MSB to dispute FDA finding in Type A meeting, page-791

Another link between Lassman & Novartis in this 2006 article headed 'Pill Pushers'. Below is an excerpt from the article.

It's funny, the more I read about Novartis the more I dislike them but still want them on side. It's sad but true what they say about big pharmas, they really do run the show.

https://www.forbes.com/forbes/2006/0508/094a.html?sh=506da41a22ed

The drug industry, of course, rejects the criticisms. Novartis says its Lamisil spending "absolutely" "in no way" has taken away resources from research into more serious diseases and that it spends far more on its cancer drugs. "Absolutely, marketing doesn't trump science--this is a science-driven industry," says Scott Lassman, a lawyer for Phrma, the industry trade group. He says makers have taken steps to curb any excesses and give ads a "more sober tone." Pfizer research chief Martin Mackay says, "We are thought of as monsters, but I don't know of a single case where we have been driven to take risks on a compound because of a marketing push. I would not let it happen."